Fig. 7: Inhibition of ACK1, SHP2 or AR activity suppresses AR transcription and prostate tumor growth by elevating pY54-H3 marks.
a VCaP cells (2 × 106/mice) were injected subcutaneously in SCID mice and once tumors were palpable ( ~ 100 mm3, in about four weeks), mice were injected with vehicle (6% Captisol), (R)-9b, SHP099, and Enzalutamide, five times a week. Mice were euthanized, tumors excised, photographed. b Tumor volumes were measured using calipers and plotted. c Tumor weights were plotted. d Tumors lysates were processed for IP with pY54-H3 antibody, followed by immunoblotting with H3 antibodies (top panel), pY-SHP2, pY-ACK1, AR, H3 and actin antibodies, respectively. Representative images are shown from n = 3 biologically independent experiments. e, f Total RNA was isolated from tumors and subjected to qRT-PCR with AR, PSA and actin primers. For a–c, e, f, n = 5 mice in each group. For b, c, e and f, data are represented as mean ± SEM. p values were determined by one-way ANOVA. p values are shown on the graph. Source data are provided as a Source Data file.
